Health
16 Oct 2026
Lakefront Biotherapeutics sells CAR‑T programs to Armed Cell Therapeutics
The Belgian company Lakefront Biotherapeutics has transferred its early‑stage CAR‑T cell therapies to Armed Cell Therapeutics for an initial payment of 8 million euros, with potential future earnings.
Read more